{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:10:32Z","timestamp":1789729832187,"version":"4.0.1"},"reference-count":11,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T00:00:00Z","timestamp":1370304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The principles of pharmacokinetic (<jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content>) dose tailoring in clinical practice, using limited blood sampling and <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ayesian <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content> analysis, have been described for factor VIII (FVIII). This study applied the same procedure to recombinant FIX (rFIX), i.e. population <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content> modelling and the use of a simplified (one\u2010compartment) model to describe only the terminal part of the coagulation factor vs. time curve. Data from a previous study on rFIX in 56 patients (4\u201356\u00a0years, 18\u2013133\u00a0kg) were used to define a three\u2010compartment population <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content> model. The average FIX clearance was 8.4\u00a0mL\u00a0h<jats:sup>\u22121<\/jats:sup>\u00a0kg<jats:sup>\u22121<\/jats:sup>. Elimination half\u2010life ranged between 14 and 27\u00a0h. Data obtained from 24\u00a0h after the infusion were found to define the terminal phase of FIX disposition. Doses to produce a target trough FIX level (set at 0.01\u00a0IU\u00a0mL<jats:sup>\u22121<\/jats:sup>) at 72\u00a0h predicted by the Bayesian analysis, with blood sampling at either 24, 48 and 72\u00a0h or at only 24 and 48\u00a0h, were within \u221240% to +67% of those predicted using the three\u2010compartment model, and within \u221257% to +125% for targeting a level at 96\u00a0h. These errors were lower than the overall interindividual variance in dose requirements. As three\u2010compartment models are needed to characterize the <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content> of both plasma\u2010derived FIX and rFIX, simplification to a one\u2010compartment model is less straightforward than for FVIII, and the methodology should be investigated further before clinical application. Limited blood sampling and Bayesian analysis could still, however, be potentially useful for targeting rFIX trough levels during prophylaxis.<\/jats:p>","DOI":"10.1111\/hae.12188","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T07:00:57Z","timestamp":1370329257000},"page":"753-757","source":"Crossref","is-referenced-by-count":44,"title":["Population pharmacokinetics of recombinant factor IX: implications for dose tailoring"],"prefix":"10.1111","volume":"19","author":[{"given":"S.","family":"Bj\u00f6rkman","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Biosciences Uppsala University Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.4.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02370.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02191.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12055"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02431.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1218.1218","article-title":"Population pharmacokinetic modeling of BeneFIX in pediatric and adult patients with hemophilia B demonstrates weight as an important factor contributing to inter\u2010patient PK variability","volume":"112","author":"Udata C","year":"2008","journal-title":"Blood"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00465.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1211-z"},{"key":"e_1_2_8_10_1","unstructured":"Centers for Disease Control and Prevention.Clinical Growth Charts.Atlanta GA. Available athttp:\/\/www.cdc.gov\/growthcharts\/. Accessed July 30 2012."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0676-x"},{"key":"e_1_2_8_12_1","volume-title":"Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","author":"Rowland M","year":"2011"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhae.12188","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.12188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:09:44Z","timestamp":1696338584000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.12188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,4]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1111\/hae.12188"],"URL":"https:\/\/doi.org\/10.1111\/hae.12188","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,4]]}}}